IMS symposium on CVD at midlife.
First speaker Prof Chrisandra Shufelt (USA).
MHT and CVD: looking back before moving forward.
KEEPS looked transdermal vs oral estrogen, using annual CIMT. No sigt diff.
#IMS2022
ELITE looked at CIMT in groups <6 or >10 yrs post menopause. Increase in CIMT was lower in the early menopause group but not at a level to affect relative risk for CVD. #IMS2022
Women with POI should receive MHT unless contraindicated. #IMS2022
Next speaker. Prof Lisa Larkin (USA)
Migraine management across the lifespan.
CVD and stroke risk inc in patients with migraine with aura. #IMS2022
Early treatment of migraine with triptans increases response and decreases recurrence.
Migraine can worsen at peri menopause and improve after menopause.
Injectable CGRP mAbs are effective.
New agents- oral CGRP ‘gepants’. #IMS2022
Next speaker. Prof Tomi Mikkola (Finland).
History of pre-eclampsia as a CVD risk factor among menopausal women. @IntlMenopause
A history of pre-eclampsia predisposes a woman to approx two fold risk of CVD later in life. #IMS2022
Hormone therapy may prevent IHD and stroke in these patients.
Just an aside. The best academics say ‘I don’t know’ quite frequently during question time.
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.